Cytek Biosciences (CTKB) Revenue (2020 - 2026)

Cytek Biosciences (CTKB) has reported Revenue for 7 consecutive years, with $48.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 5.57% year-over-year to $48.1 million; the trailing twelve-month figure through Jun 2026 stood at $206.7 million (up 5.44% YoY), and the FY2025 full-year result was $201.5 million, up 0.52% from the prior year.
• Revenue rose to $48.1 million in Q2 2026 per CTKB's latest filing, from $44.1 million in the prior quarter.
• Across five years, Revenue topped out at $62.1 million in Q4 2025 and bottomed at $35.1 million in Q1 2022.
• Historically, Revenue has averaged $47.3 million across 5 years, with a median of $47.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue soared 44.46% in 2022, then retreated 7.59% in 2025.
• Over 5 years, Revenue stood at $48.3 million in 2022, then grew by 20.48% to $58.2 million in 2023, then dropped by 1.3% to $57.5 million in 2024, then gained by 8.12% to $62.1 million in 2025, then dropped by 22.53% to $48.1 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $48.1 million, $44.1 million, and $62.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.